Cagrilintide – Mechanism, Use & Clinical Trials
Cagrilintide is a long-acting amylin analogue under investigation for the treatment of obesity and type 2 diabetes, reducing appetite and regulating blood sugar levels.
Wissenswertes über "Cagrilintide"
Cagrilintide is a long-acting amylin analogue under investigation for the treatment of obesity and type 2 diabetes, reducing appetite and regulating blood sugar levels.
What is Cagrilintide?
Cagrilintide is an investigational, long-acting amylin analogue -- a synthetic peptide hormone structurally similar to the naturally occurring hormone amylin (also known as Islet Amyloid Polypeptide, or IAPP). Amylin is co-secreted with insulin by the beta cells of the pancreas and plays a key role in regulating blood glucose levels and satiety. Cagrilintide is being developed by the Danish pharmaceutical company Novo Nordisk and is currently being evaluated in clinical trials, including in combination with the GLP-1 receptor agonist semaglutide (under the project name CagriSema).
Indications
Cagrilintide is primarily being investigated for the following conditions:
- Obesity: For weight reduction in adults with a body mass index (BMI) of 30 or above.
- Type 2 diabetes mellitus: To improve glycaemic control in patients with insufficient blood sugar management.
- Combination therapy: In conjunction with other agents such as semaglutide, to achieve synergistic effects on body weight and blood glucose.
Mechanism of Action
Cagrilintide mimics the action of the natural hormone amylin by binding to amylin receptors in the brain and peripheral tissues. Its key pharmacological effects include:
- Slowing of gastric emptying: Food passes more slowly from the stomach into the small intestine, prolonging the feeling of fullness after meals.
- Appetite suppression: Activation of amylin receptors in the hypothalamus -- the brain region controlling hunger and satiety -- reduces food intake.
- Inhibition of glucagon secretion: Cagrilintide suppresses the release of glucagon, a hormone that raises blood sugar levels, thereby contributing to better glycaemic control.
- Extended half-life: Compared to native amylin, cagrilintide has a significantly prolonged duration of action, enabling once-weekly subcutaneous administration.
Dosage and Administration
Cagrilintide is administered as a subcutaneous injection (under the skin). In clinical trials, it is typically given once weekly, simplifying treatment for patients. Doses of up to 2.4 mg per week have been investigated in the SCALE trials and CagriSema combination studies. As the compound is still under clinical development, no officially approved standard dosage has yet been established.
Clinical Trial Results
Phase 2 and Phase 3 studies have shown promising results for cagrilintide:
- As a monotherapy, cagrilintide achieved significant weight loss compared to placebo.
- In combination with semaglutide (CagriSema), particularly pronounced weight reductions were observed -- exceeding 20% of baseline body weight in some study arms.
- The combination also demonstrated favourable effects on HbA1c (long-term blood glucose marker) and cardiovascular risk factors.
Side Effects
As with other peptide hormone analogues, the most common side effects of cagrilintide are gastrointestinal in nature and include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Decreased appetite
These side effects typically occur at the start of treatment and diminish over time in most patients. More serious adverse events, such as pancreatitis (inflammation of the pancreas), have been reported in association with amylin analogues and are being carefully monitored in ongoing trials.
Treatment Context and Outlook
Cagrilintide represents part of a new generation of combination therapies targeting obesity and type 2 diabetes. By simultaneously activating multiple hormonal pathways -- specifically the amylin and GLP-1 signalling axes -- this approach aims to achieve superior efficacy compared to single-agent treatments. If ongoing Phase 3 trials are successful, cagrilintide could be submitted for regulatory approval as part of a fixed-dose combination with semaglutide in the coming years.
References
- Enebo LB et al. - Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management. The Lancet (2021). https://doi.org/10.1016/S0140-6736(21)01238-X
- Novo Nordisk - CagriSema Phase 3 Clinical Trial Program (REDEFINE). Novo Nordisk Pipeline Information (2023). https://www.novonordisk.com
- Dehestani B et al. - Amylin as a potential target for the treatment of obesity and metabolic disorders. Diabetes, Obesity and Metabolism (2022). https://doi.org/10.1111/dom.14720
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryGonadorelin
Delta sleep-inducing peptide
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Cagrilintide + Cagrilintid